Coherus BioSciences Inc
Company & Industry Overviews
Mylan’s Biosimilar of Neulasta Expected to Be a Key Growth Driver
Mylan (MYL) received FDA approval for Fulphila in June, and the drug was launched in the United States in July.
Biosimilars: Why You Can Expect Opportunity Ahead
Biosimilars and Increased Complexity Generic drug manufacturers have recently moved into more complex products. One example is biosimilars, generic copies of molecularly complex biologic drugs. Biosimilars are beginning to take a foothold in the U.S. Importantly, they are much more difficult to replicate, than regular generics, which equates to high barriers to entry. This may […]